AR125238A1 - Inhibidores de khk - Google Patents
Inhibidores de khkInfo
- Publication number
- AR125238A1 AR125238A1 ARP220100751A ARP220100751A AR125238A1 AR 125238 A1 AR125238 A1 AR 125238A1 AR P220100751 A ARP220100751 A AR P220100751A AR P220100751 A ARP220100751 A AR P220100751A AR 125238 A1 AR125238 A1 AR 125238A1
- Authority
- AR
- Argentina
- Prior art keywords
- disease
- kidney
- syndrome
- fibrosis
- renal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163167331P | 2021-03-29 | 2021-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125238A1 true AR125238A1 (es) | 2023-06-28 |
Family
ID=81388962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100751A AR125238A1 (es) | 2021-03-29 | 2022-03-29 | Inhibidores de khk |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12410160B2 (https=) |
| EP (2) | EP4313967B1 (https=) |
| JP (2) | JP7705475B2 (https=) |
| KR (1) | KR20230158542A (https=) |
| CN (1) | CN117120429A (https=) |
| AR (1) | AR125238A1 (https=) |
| AU (2) | AU2022252182B2 (https=) |
| CA (1) | CA3214961A1 (https=) |
| ES (1) | ES3061522T3 (https=) |
| PL (1) | PL4313967T3 (https=) |
| TW (2) | TWI855308B (https=) |
| WO (1) | WO2022212194A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230098069A (ko) * | 2021-12-24 | 2023-07-03 | 주식회사 엘지화학 | (s)-2-(2-메틸아제티딘-1-일)피리미딘 유도체 및 이를 포함하는 약제학적 조성물 |
| JP2025534728A (ja) * | 2022-10-24 | 2025-10-17 | ユーハン・コーポレイション | ジメチル－２，３－ジヒドロ－１ｈ－インデン誘導体の改良された製造方法 |
| WO2024125482A1 (zh) * | 2022-12-13 | 2024-06-20 | 华领医药技术（上海）有限公司 | 作为己酮糖激酶抑制剂的化合物、其用途以及包含其的组合物 |
| WO2025184056A1 (en) * | 2024-02-26 | 2025-09-04 | Miralogx Llc | Synthetic cannabinoid analogs, pharmaceutical compositions and methods of treating anxiety and other disorders |
| WO2025250674A1 (en) * | 2024-05-30 | 2025-12-04 | Miralogx Llc | Synthetic cannabinoid analogs, pharmaceutical compositions and methods of treating neurological disorders and other conditions |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041443A (en) * | 1989-02-21 | 1991-08-20 | Dainippon Pharmaceutical Co., Ltd. | Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof |
| US5137890A (en) | 1990-02-14 | 1992-08-11 | Ortho Pharmaceutical Corporation | 4-phenyl tetrahydropyrido(4,3-d)pyrimidines |
| GB0100620D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical cokpounds V |
| ES2305744T3 (es) * | 2003-03-12 | 2008-11-01 | Millennium Pharmaceuticals, Inc. | Derivados de quinazolina como inhibidores e tgf-beta. |
| BRPI0415683A (pt) * | 2003-11-03 | 2006-12-19 | Warner Lambert Co | inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central |
| CN101277700B (zh) | 2005-08-04 | 2013-02-20 | 詹森药业有限公司 | 作为5-羟色胺受体调节剂的嘧啶化合物 |
| US7851468B2 (en) * | 2006-05-15 | 2010-12-14 | Cephalon, Inc. | Substituted pyrazolo[3,4-d]pyrimidines |
| EP2209785A1 (en) * | 2007-10-05 | 2010-07-28 | S*BIO Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| US8829011B2 (en) | 2008-10-29 | 2014-09-09 | Janssen Pharmaceutica Nv | 2-aminopyrimidine compounds as serotonin receptor modulators |
| US8586582B2 (en) * | 2008-11-11 | 2013-11-19 | Xcovery Holding Company, Llc | PI3K/mTOR kinase inhibitors |
| TWI491606B (zh) | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| JP2013525370A (ja) | 2010-04-22 | 2013-06-20 | ヤンセン ファーマシューティカ エヌ．ベー． | ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物 |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| LT2776038T (lt) | 2011-11-11 | 2018-04-25 | Gilead Apollo, Llc | Acc inhibitoriai ir jų panaudojimas |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| CN103467482B (zh) * | 2012-04-10 | 2017-05-10 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用 |
| EP3197448B1 (en) | 2014-09-24 | 2019-04-24 | Gilead Sciences, Inc. | Methods of treating liver disease |
| TWI685491B (zh) | 2014-12-23 | 2020-02-21 | 美商基利科學股份有限公司 | 製備５-（４-環丙基-１ｈ-咪唑-１-基）-ｎ-（６-（４-異丙基-４ｈ-１,２,４-三唑-３-基）吡啶-２-基）-２-氟-４-甲基苯甲醯胺之方法 |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| JP2018501276A (ja) | 2015-01-09 | 2018-01-18 | ギリアド アポロ， エルエルシー | 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 |
| US20190137505A1 (en) * | 2015-08-10 | 2019-05-09 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Biomarkers of methylglyoxal and related methods thereof |
| SI3397631T1 (sl) | 2015-12-29 | 2022-01-31 | Pfizer Inc. | Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze |
| CN119977993A (zh) | 2016-03-02 | 2025-05-13 | 吉利德阿波罗公司 | 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法 |
| EP4273132A3 (en) | 2017-03-03 | 2024-01-10 | Gilead Sciences, Inc. | Processes for preparing acc inhibitors and solid forms thereof |
| US11083720B2 (en) | 2017-03-17 | 2021-08-10 | Regents Of The University Of Colorado, A Body Corporate | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases |
| WO2018183342A1 (en) | 2017-03-28 | 2018-10-04 | Gilead Sciences, Inc. | Methods of treating liver disease |
| PT3600309T (pt) | 2017-03-28 | 2022-10-03 | Gilead Sciences Inc | Combinações terapêuticas para o tratamento de doenças hepáticas |
| AU2018250614A1 (en) | 2017-04-12 | 2019-10-17 | Gilead Sciences, Inc. | Methods of treating liver disease |
| KR102419458B1 (ko) | 2017-10-06 | 2022-07-12 | 길리애드 사이언시즈, 인코포레이티드 | Acc 억제제를 포함하는 조합 요법 |
| US12161621B2 (en) | 2018-07-16 | 2024-12-10 | The Regents Of The University Of Colorado | Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease |
| TWI714231B (zh) | 2018-09-04 | 2020-12-21 | 美商美國禮來大藥廠 | 2,6-二胺基吡啶化合物 |
| KR102558308B1 (ko) | 2018-09-27 | 2023-07-24 | 주식회사 엘지화학 | 3-아자바이사이클로[3,1,1]헵탄 유도체 및 이를 포함하는 약제학적 조성물 |
| PH12021551635A1 (en) * | 2019-01-29 | 2022-05-02 | Shandong Xuanzhu Pharma Co Ltd | Hexone glucokinase inhibitor and use thereof |
| CA3233305A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| WO2020185685A1 (en) | 2019-03-08 | 2020-09-17 | The Regents Of The University Of California | Compositions and methods for treating acne |
| CN114007602A (zh) | 2019-04-17 | 2022-02-01 | 科罗拉多研究合作伙伴有限责任公司 | 治疗果糖相关病症或疾病的新型化合物和使用方法 |
| CN111978296A (zh) | 2019-05-22 | 2020-11-24 | 山东轩竹医药科技有限公司 | 己酮糖激酶抑制剂及其用途 |
| TWI750685B (zh) | 2019-06-17 | 2021-12-21 | 美商美國禮來大藥廠 | 二取代吡唑化合物 |
| EP4083034A4 (en) | 2019-12-24 | 2023-12-06 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | ASSOCIATION WITH CHAD-INHIBITING EFFECT |
| CN114846008B (zh) | 2019-12-25 | 2024-05-28 | 杭州中美华东制药有限公司 | 具有果糖激酶(khk)抑制作用的嘧啶类化合物 |
| WO2021162943A1 (en) | 2020-02-13 | 2021-08-19 | Eli Lilly And Company | 2-[2-methylazetidin-1-yl]-4-phenyl-6-(trifluoromethyl)-pyrimidine compounds |
| CN111423420A (zh) | 2020-04-30 | 2020-07-17 | 广州博济医药生物技术股份有限公司 | 作为己酮糖激酶抑制剂的并环化合物 |
| CN114181198B (zh) | 2020-09-15 | 2025-07-15 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类己酮糖激酶抑制剂及其用途 |
| EP4269404A4 (en) * | 2020-12-25 | 2024-12-04 | Xizang Haisco Pharmaceutical Co., Ltd. | KETOHEXOKINASE INHIBITORS AND USE THEREOF |
| CN114805312A (zh) | 2021-01-29 | 2022-07-29 | 上海拓界生物医药科技有限公司 | 一种己酮糖激酶抑制剂及其制备方法 |
| CN114989143A (zh) | 2021-03-02 | 2022-09-02 | 山东轩竹医药科技有限公司 | 并环类己酮糖激酶抑制剂及其用途 |
| WO2022211595A1 (ko) | 2021-04-01 | 2022-10-06 | 주식회사 엘지화학 | 옥사디아졸 화합물 및 이를 포함하는 약제학적 조성물 |
-
2022
- 2022-03-25 CA CA3214961A patent/CA3214961A1/en active Pending
- 2022-03-25 CN CN202280024429.7A patent/CN117120429A/zh active Pending
- 2022-03-25 WO PCT/US2022/021912 patent/WO2022212194A1/en not_active Ceased
- 2022-03-25 ES ES22719399T patent/ES3061522T3/es active Active
- 2022-03-25 KR KR1020237035032A patent/KR20230158542A/ko active Pending
- 2022-03-25 AU AU2022252182A patent/AU2022252182B2/en active Active
- 2022-03-25 EP EP22719399.2A patent/EP4313967B1/en active Active
- 2022-03-25 US US17/704,440 patent/US12410160B2/en active Active
- 2022-03-25 JP JP2023560087A patent/JP7705475B2/ja active Active
- 2022-03-25 PL PL22719399.2T patent/PL4313967T3/pl unknown
- 2022-03-25 EP EP25206447.2A patent/EP4681774A3/en active Pending
- 2022-03-28 TW TW111111557A patent/TWI855308B/zh active
- 2022-03-28 TW TW113132589A patent/TW202448875A/zh unknown
- 2022-03-29 AR ARP220100751A patent/AR125238A1/es not_active Application Discontinuation
-
2024
- 2024-12-04 JP JP2024211090A patent/JP7778900B2/ja active Active
-
2025
- 2025-05-19 AU AU2025203602A patent/AU2025203602A1/en active Pending
- 2025-08-22 US US19/307,911 patent/US20260092053A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI855308B (zh) | 2024-09-11 |
| KR20230158542A (ko) | 2023-11-20 |
| JP2025032196A (ja) | 2025-03-11 |
| WO2022212194A1 (en) | 2022-10-06 |
| PL4313967T3 (pl) | 2026-04-20 |
| TW202448875A (zh) | 2024-12-16 |
| EP4313967B1 (en) | 2025-11-12 |
| US12410160B2 (en) | 2025-09-09 |
| CA3214961A1 (en) | 2022-10-06 |
| TW202246253A (zh) | 2022-12-01 |
| EP4681774A2 (en) | 2026-01-21 |
| AU2022252182B2 (en) | 2025-02-20 |
| CN117120429A (zh) | 2023-11-24 |
| AU2022252182A1 (en) | 2023-09-28 |
| JP2024512646A (ja) | 2024-03-19 |
| ES3061522T3 (en) | 2026-04-06 |
| EP4313967A1 (en) | 2024-02-07 |
| EP4313967C0 (en) | 2025-11-12 |
| US20230079863A1 (en) | 2023-03-16 |
| JP7778900B2 (ja) | 2025-12-02 |
| JP7705475B2 (ja) | 2025-07-09 |
| EP4681774A3 (en) | 2026-03-25 |
| AU2025203602A1 (en) | 2025-06-05 |
| US20260092053A1 (en) | 2026-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125238A1 (es) | Inhibidores de khk | |
| ECSP17004665A (es) | Ácidos grasos novedosos y su uso en la conjugación con biomoléculas | |
| MX2022004942A (es) | Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos. | |
| AR123156A1 (es) | Agonistas de glp-1r y sus usos | |
| MX2021012492A (es) | Agonistas de glp-1r y usos de los mismos. | |
| PE20251598A1 (es) | Analogos de incretina y sus usos | |
| MX2018014743A (es) | Metodo para tratar fibrosis hepatica. | |
| HRP20200881T1 (hr) | Antitijela koja vežu beta-klotho domenu 2 i postupci njihove uporabe | |
| CU24540B1 (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| PE20220377A1 (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa | |
| DOP2021000027A (es) | Compuestos de 2,6-diaminopiridina | |
| PE20171622A1 (es) | Formulacion de relacion fija de insulina glargina/lixisenatida | |
| EA201592020A1 (ru) | Новая композиция для неалкогольной жировой болезни печени (нажбп) | |
| AR084215A1 (es) | Bifidobacterium cect 7765 y su uso en la prevencion y/o tratamiento del sobrepeso, la obesidad y patologias asociadas | |
| EA201391262A1 (ru) | Композиция, способ лечения и диагностики стеатоза печени как самостоятельного заболевания или в комбинации с инфекцией гепатита с | |
| BRPI0412380A (pt) | compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos | |
| PH12019550226A1 (en) | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
| MX2020011225A (es) | Tetrazol que contiene inhibidores de la cinasa 1 reguladora de la señal de apoptosis y métodos de uso de los mismos. | |
| AR125400A1 (es) | Compuestos de péptidos similares al glucagón | |
| ZA202304148B (en) | Preparation of benzimidazolone derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors | |
| ZA202304150B (en) | Preparation of oxindole derivatives as novel diacylglyceride o-acyltransferase 2 inhibitors | |
| EA202092057A1 (ru) | Защитные композиции для печени и терапевтические применения | |
| CL2025001515A1 (es) | Uso de finerenona para tratar la enfermedad renal crónica en la diabetes mellitus tipo i. | |
| MX2022007929A (es) | Coagonistas de triazol grapados de los receptores de glucagon y glp-1. | |
| AR132060A1 (es) | Compuestos heterocíclicos como antagonistas de sting |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |